Bimekizumab safety in moderate to severe plaque psoriasis: Rates of hepatic events and changes in liver parameters over 2 years in randomized phase 3/3b trials

By sjmartinez • April 9, 2024

Lebwohl M, Merola JF, Strober B, Armstrong A, Yoshizaki A, Gisondi P, Szilagyi B, Peterson L, de Cuyper D, Cross N, Davies O, Gottlieb AB. Bimekizumab safety in moderate to severe plaque psoriasis: Rates of hepatic events and changes in liver parameters over 2 years in randomized phase 3/3b trials. J Am Acad Dermatol. 2024 Apr 6:S0190-9622(24)00568-1. doi: 10.1016/j.jaad.2024.03.041. Epub ahead of print. PMID: 38588819.

Tags: alanine aminotransferase, aspartate aminotransferase, bimekizumab, Dermatology, enzyme, Hepatic, Liver, liver fibrosis, plaque psoriasis, psoriasis, Publications, safety, transaminase

The Association between Obesity and Efficacy of Psoriasis Therapies: An Expert Consensus Panel

Burshtein J, Armstrong A, Chow M, DeBusk L, Glick B, Gottlieb AB, Gold LS, Korman NJ, Lio P, Merola J, Rosmarin D, Rosenberg A, Van[...]

Increased mitochondrial mutation heteroplasmy induces aging phenotypes in pluripotent stem cells and their differentiated progeny

Vandiver AR, Torres A Jr, Sanden A, Nguyen TL, Gasilla J, Doan MT, Martirosian V, Hoang A, Wanagat J, Teitell MA. Increased mitochondrial mutation heteroplasmy[...]

Update on Absorbable Facial Thread Lifts

Riopelle AM, Geisler AN, Eber A, Dover JS. Update on Absorbable Facial Thread Lifts. Dermatol Surg. 2024 Dec 11. doi: 10.1097/DSS.0000000000004521. Epub ahead of print.[...]